AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03126786
Drug: SC CLS-TA
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLS-TA \[4 mg/100 μL\] SC injection
Trial: NCT02342392
Drug: ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intralesional ranibizumab 0.3 mg/0.03mL injected 1 week before pterygium excision surgery.
Trial: NCT01679392
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unilateral, single shot, ultrasound-guided, transversus abdominis plane block with 20 ml ropivacaine (7.5 mg/ml)
Trial: NCT03128619
Drug: Copanlisib
RxNorm normalized name: Copanlisib
DrugBank: Copanlisib (DB12483)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03128619
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03128619
Drug: Palbociclib
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT00730990
Drug: PET Scan with PF-03654746
RxNorm normalized name: Pet-ema
DrugBank: PF-03654746 (DB12201)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If none of the data from Cohort 2 is informative, then: 2) an additional 3 subjects will receive 2 Scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746. Doses will be determined based upon the outcome of the first intervention.
Trial: NCT00730990
Drug: PET Scan with PF-03654746
RxNorm normalized name: Pet-ema
DrugBank: PF-03654746 (DB12201)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If none of the data from the previous interventions are informative, then: 3) an additional 3 patients will receive 2 scans on Day 1 and 1 scan on Day 2 following three different doses of PF-0365476. Doses will be determined based upon the outcomes of the previous interventions.
Trial: NCT04211012
Drug: Toripalimab plus Nab-Paclitaxel +/- cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Toripalimab injection (JS001): 240mg, i.v.gtt, q3w; Nab-Paclitaxel: 260mg/m2, i.v.gtt, q3w Cisplatin: total dosage of 70 mg/m2 i.v.gtt, q3w，, complete all doses within the first 2 days of each cycle.~Study treatment will be continued until disease progression or intolerable toxicity, or withdrawal at the discretion of the investigator or the subject, loss to follow-up, or initiation of other anti-cancer therapy, or death, whichever occurs first. Toripalimab will be administered no more than 2 years,and nab-paclitaxel with or without cisplatin will be administered up to 6 cycles.. If the subject is intolerable to cisplatin treatment according to the investigator's judgment, JS001 + Nab-Paclitaxel may be dosed.~Dosing sequence: Toripalimab, Nab-Paclitaxel, cisplatin
Trial: NCT00991289
Drug: Nitazoxanide (NTZ)
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg twice daily, taken orally with food
Trial: NCT00991289
Drug: Pegylated interferon alfa-2a (PEG)
RxNorm normalized name: Pegylated-interferon alfa 2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180 micrograms via subcutaneous injection once weekly
Trial: NCT00991289
Drug: Ribavirin (RBV)
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weight-based dosing; 1,000 mg daily, taken orally, for people weighing less than 75 kg or 1,200 mg for people weighing at least 75 kg.
Trial: NCT01954238
Drug: GCC-4401C
RxNorm normalized name: Oristar gcc
DrugBank: Glyceryl monocaprylate (DB19362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease.~* The dose selection for this clinical study was based on the safety, Pharmacokinetics and Pharmacodynamics results of the single dose study.~* GCC-4401C was well tolerated in the single ascending dose study up to the highest single oral dose administered of 80 mg from 2.5 mg in 48 subjects.~* The study consists of five cohorts (10 mg, 20 mg, 40 mg, 60 mg, and 80 mg) with eight subjects per cohort.~* In the 20 mg cohort, six additional subjects will receive rivaroxaban (Xarelto®) 20 mg as an active comparator in open-label fashion.
Trial: NCT01954238
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban (Xarelto®) 20 mg tablets for oral administration IMP, placebo and comparator will be administered the same time points. The comparator will be administered open-label 30 minutes after a standard breakfast.
Trial: NCT01211145
Drug: Zolmitriptan
RxNorm normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5 mg nasal spray
Trial: NCT01211145
Drug: Zolmitriptan
RxNorm normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg nasal spray
Trial: NCT01211145
Drug: Zolmitriptan
RxNorm normalized name: Zolmitriptan
DrugBank: Zolmitriptan (DB00315)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5.0 mg nasal spray
Trial: NCT01234597
Drug: INSULIN GLARGINE (HOE901)
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Trial: NCT01234597
Drug: INSULIN GLULISINE (HMR1964)
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
Trial: NCT01442662
Drug: pazopanib + gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: pazopanib tablets (200mg) per os, 800mg/day continuously gemcitabine IV, 2 injection per cycle
Trial: NCT01518569
Drug: ulinastatin
RxNorm normalized name: ulinastatin
DrugBank: Ulinastatin (DB12038)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ulinastatin 5000 unit/kg iv before the initiation of CPB
Trial: NCT03292185
Drug: insulin degludec/liraglutide
RxNorm normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the thigh.
Trial: NCT03292185
Drug: insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 17 U Insulin Degludec, single dose administration under the skin in the thigh.
Trial: NCT03292185
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.6 mg Liraglutide, single dose administration under the skin in the thigh
Trial: NCT04842370
Drug: PHI-101
RxNorm normalized name: PHI-101
DrugBank: PHI-101 (DB17237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PHI-101, oral, once-daily administration, consisting of 28-days per 1 cycle
Trial: NCT01373151
Drug: BMS-945429 Placebo
RxNorm normalized name: BMS-945429
DrugBank: Clazakizumab (DB12849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection, Subcutaneous, 0 mg, Every 4 weeks, Day 1 - Week 24 only
Trial: NCT03421379
Drug: Glucagon Nasal Powder
RxNorm normalized name: glucagon Nasal Powder
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intranasally
Trial: NCT03421379
Drug: Glucagon Hydrochloride Solution
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IM
Trial: NCT00120705
Drug: darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04058028
Drug: Rozibafusp Alfa
RxNorm normalized name: Rozibafusp Alfa
DrugBank: Rozibafusp Alfa (DB19233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rozibafusp Alfa will be presented in 5 mL glass vial
Trial: NCT01373151
Drug: Adalimumab Placebo
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks
Trial: NCT01373151
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Injection, Subcutaneous, 40 mg, Every 2 weeks, 48 weeks
Trial: NCT04058028
Drug: Placebo for Rozibafusp Alfa
RxNorm normalized name: Rozibafusp Alfa
DrugBank: Rozibafusp Alfa (DB19233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Rozibafusp Alfa will be presented in 5 mL glass vial
Trial: NCT00730990
Drug: PET Scan with PF-03654746
RxNorm normalized name: Pet-ema
DrugBank: PF-03654746 (DB12201)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 2 of the study will have 3 possible interventions:~1) 3 subjects in Cohort 2 will receive 2 scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746 (0.5 mg, 1.5 mg, 4 mg).
Trial: NCT03840837
Drug: Rivastigmine transdermal patch
RxNorm normalized name: rivastigmine Transdermal Product
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Titration of transdermal rivastigmine, as per arm description.
Trial: NCT02011958
Drug: Liposomal Amphotericin B
RxNorm normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg/kg total dose: IV infusion of 5mg/kg per day on day 1 to 5, 10,17,24 (when administered as a monotherapy)~30 mg/kg total dose: IV infusion 5 mg/kg per day on day 1, 3, 5, 7, 9, 11 (when administered in combination with Miltefosine)
Trial: NCT02186600
Drug: Calcium Carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Used as daily supplement to ensure subject obtains 1200 mg of calcium per day (diet + supplement)
Trial: NCT02186600
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive Vitamin D3 supplements to ensure serum level of Vitamin D is at least 30 ng/ml.
Trial: NCT00296855
Drug: Vasovist (BAY86-5283, MS-325)
RxNorm normalized name: MS-1819
DrugBank: Gadofosveset trisodium (DB06705)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients receive a single IV bolus injection of Vasovist at a dose of 0,03 mmol/kg BW at a flowrate of 0,5 mL/sec, followed by a saline flush of at least 30 mL
Trial: NCT02186600
Drug: Risedronate
RxNorm normalized name: Risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Risedronate 35 mg orally will be ingested weekly by subjects in Risedronate group.
Trial: NCT02011958
Drug: Miltefosine
RxNorm normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Orally taken every day during 28 days~* 1 x 50 mg capsule per day if the patient weights less or equal to 25 kg~* 2 x 50 mg capsules per day if the patient weights more than 25 kg (1 capsule in the morning / 1 capsule in the evening)
Trial: NCT00437125
Drug: Duloxetine hydrochloride
RxNorm normalized name: Duloxetine Hydrochloride
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duloxetine 30 milligram (mg) once daily (QD) orally (PO) for 1 week, then duloxetine 60 mg QD PO for 11 weeks
Trial: NCT01397422
Drug: ADS-5102 (extended release amantadine HCl)
RxNorm normalized name: Stahist AD
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral capsules to be administered once daily at bedtime, for 8 weeks
Trial: NCT03311464
Drug: adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Study drug will be administered subcutaneously.
Trial: NCT02801032
Drug: Tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose, 20 mg capsule p.o. minimum one week apart from placebo.~MRI of cerebrum before the first trial day.~Transcranial Doppler to measure blood flow velocity in MCA bilaterally before and after intervention.~Near-infrared spectroscopy (NIRS) to measure cortical brain oxygenation before and after intervention.~EndoPAT2000 to estimate endothelial function before and after intervention.~Endothelial biomarkers in blood samples before and after intervention.
Trial: NCT01939730
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m\^2 by vein once a week for 4 weeks on Days 1, 8, 15, 22.
Trial: NCT01939730
Drug: GM-CSF
RxNorm normalized name: GM-CSF
DrugBank: Regramostim (DB05386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mcg subcutaneously 3 times a week for 8 weeks.
Trial: NCT03291821
Drug: human menopausal gonadotropin
RxNorm normalized name: Human menopausal gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: human menopausal gonadotropin subcutaneously
Trial: NCT03291821
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist subcutaneously
Trial: NCT03079115
Drug: High-dose Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: high-dose Atorvastatin (80 mg QD from 3 days before to 3 days after CAS, and thereafter 20mg QD until 30 days after CAS)
Trial: NCT03079115
Drug: Conventional-dose Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: conventional-dose Atorvastatin(20 mg QD from 3 days before to 30 days after CAS).
Trial: NCT02367547
Drug: Hexylaminolevulinate cream
RxNorm normalized name: aminolevulinate
DrugBank: Methyl aminolevulinate (DB00992)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The cream is mixed up by the Pharmacy Yliopiston Apteekki for the study and every set is analysed by mass spectrometry.
Trial: NCT03204695
Drug: Anticoagulation or Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects either continue on anticoagulation or receive clopidogrel
Trial: NCT03241043
Drug: Treatment 2 weeks Envarsus followed by 2 weeks Advagraf
RxNorm normalized name: Envarsus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03241043
Drug: Treatment 2 weeks Advagraf followed by 2 weeks Envarsus
RxNorm normalized name: Envarsus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03122691
Drug: cannabis
RxNorm normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis will be self-administered by study participants
Trial: NCT01296139
Drug: Ferumoxytol
RxNorm normalized name: Ferumoxytol
DrugBank: Ferumoxytol (DB06215)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All subjects will undergo pre-injection, 24, 48 hours post-Ferumoxytol injection (dose of 7.5mg/kg Fe) MRI consisting of T1 weighted (W), T2W and T2\*W MRI in a 3 Tesla magnet. Additionally, all subjects will undergo pre-injection, 24 hours, 48 hours post-Ferumoxytol injection (dose of 7.5mg/kg Fe) ultrasound.
Trial: NCT01315275
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02176369
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule soft (20/30 mg) - 50 mg three times a week (monday, wednesday and friday) for a three weeks cycle (then recycled the next week at the same doses)Treatment will be continued until progression, unacceptable toxicity or death.
Trial: NCT01014598
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given intra-arterially via isolated lung suffusion
Trial: NCT02374320
Drug: liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injected as an axillary block
Trial: NCT00556348
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.25mg
Trial: NCT02527824
Drug: Oxaliplatin, Irinotecan, S-1
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment will be delivered every 2 weeks~1. Oxaliplatin 65 mg/m2 iv on day 1~2. Irinotecan 135 mg/m2 iv on day 1~3. S-1 80 mg/m2/day on day1-7
Trial: NCT00650819
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe 10 mg plus simvastatin placebo once daily for 8 weeks
Trial: NCT01381926
Drug: exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: exenatide 5mcg sq twice daily for one month and exenatide 10mcg twice daily for month 2. The 3rd month is a washout period. Month 4 and 5 saline placebo is given as 5mcg and 10mcg respectively.
Trial: NCT01602952
Drug: Radotinib
RxNorm normalized name: Radotinib
DrugBank: Radotinib (DB12323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg, 100mg or 200mg Capsule BID
Trial: NCT01525238
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet, Oral, 2.5 mg, Single-dose
Trial: NCT01525238
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet, Oral, 5 mg, Single-dose
Trial: NCT01525238
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablet, Oral, 10 mg, Single-dose
Trial: NCT02371590
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The starting dose for all patients is 5 mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, as tolerated.~The study consists of a 6 month treatment period with obinutuzumab and lenalidomide, and an indefinite period of treatment with lenalidomide for as long as it is helpful and tolerated by subject.
Trial: NCT04616274
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This prospective study will draw blood from every patient to measure the venetoclax blood concentration. After blood concentration analysis by ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS), the investigator will report the concentration to clinicians.
Trial: NCT02371590
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Obinutuzumab is administered as follows: Cycle 1: 100mg IV on day 1, 900 mg IV on day 2, 1000mg day 8, 1000 mg on day 15. Cycles 2-6: 1000mg IV on day 1.
Trial: NCT01381926
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Month 1 and 2 saline placebo is given as a low and high dose respectively. The 3rd month is a washout period. Month 4 exenatide 5mcg sq twice daily and for month 5 exenatide 10mcg twice daily is administered.
Trial: NCT00963976
Drug: labetalol/hydralazine/enalapril
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
Trial: NCT00058071
Drug: amifostine trihydrate
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00049725
Drug: Daclizumab
RxNorm normalized name: Daclizumab
DrugBank: Daclizumab (DB00111)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01212094
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02959138
Drug: Lanraplenib.
DrugBank: Lanraplenib (DB14770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg (2 X 10 mg) tablets administered orally in a fasted state on Day 1
Trial: NCT04311710
Drug: ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified Dose on Specified Days
Trial: NCT04311710
Drug: nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified Dose on Specified Days
Trial: NCT03738423
Drug: REGN3500
RxNorm normalized name: Immunoglobulin igg4 (230-proline), anti-(human interleukin 33) (human monoclonal regn3500 .gamma.4-chain), disulfide with human monoclonal regn3500 .kappa.-chain, dimer
DrugBank: Itepekimab (DB16206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneous (SC)
Trial: NCT00086255
Drug: Tiagabine
RxNorm normalized name: Tiagabine
DrugBank: Tiagabine (DB00906)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00532909
Drug: Vandetanib
RxNorm normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg or 300mg By mouth every day continuous
Trial: NCT00532909
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dosage: 130mg/m2. IV Day 1 of a 21 day cycle or reduced dose of 100mg/m2 IV Day 1.
Trial: NCT00532909
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosage: 7.5mg/kg or 10mg/kg. IV Day 1 (21 day cycle)
Trial: NCT02656329
Drug: Iobenguane I -123 Injection
RxNorm normalized name: IOBENGUANE I 123
DrugBank: Iobenguane (DB06704)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iobenguane I-123 Injection, AdreView. All participants scheduled for an Iobenguane I-123 Injection, AdreView scan.
Trial: NCT00669318
Drug: pentostatin
RxNorm normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
FDA approved: yes
EMA approved: no
PMDA approved: no